BioCardia, Inc. BCDA 深 沪
等待开盘 05-21 09:30:00 美东时间
0.9115
-0.039
-4.14%
华盛通- 最 高0.96
- 今 开0.96
- 成交量 10.63万股
- 最 低 0.8811
- 昨 收 0.9509
- 总市值 997.21万
- 52周最高 2.45
- 市盈率 静 --
- 换手率 0.97%
- 52周最低 0.8404
- 委 比 -14.29%
- 总股本 1094.04万
- 历史最高 129.00
- 量 比 0.58
- 振 幅 8.30%
- 历史最低 0.8404
- 每 手 1
- 风险率 0.41%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多电话会总结 ｜ BioCardia(BCDA)2026财年Q1业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据BioCardia业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩：- **净亏损**：2026年第一季度净亏损230万美元，较2025年同期的270万美元减少40万美元 - **总费用**：2026年第一季度总费用230万美元，较上一季度减少46万美元 - **运营现金流**：2026年第一季度运营活动净现金使用170万美元，略高于2025年同期的160万美元 - **现金及现金等价物**：季度末余额为95.1万美元 ## 2. 财务指标变化：- **研发费用**：同比下降29.5万美元至120万美元（2025年第一季度为150万美元
05-19 12:17
BioCardia Q1 2026 Earnings Call: Complete Transcript
BioCardia (NASDAQ:BCDA) released first-quarter financial results and hosted an ...
05-16 04:54
BioCardia Q1 EPS $(0.21) Misses $(0.17) Estimate
BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.17) by 23.53 percent. This is a 64.41 percent increase over losses of $(0.59) per share from the
05-15 20:20
Earnings Scheduled For May 15, 2026
Companies Reporting Before The Bell • Traws Pharma (NASDAQ:TRAW) is expected to...
05-15 19:11
BioCardia Says FDA Raised No Safety Concerns, Outlines Two Clearance Pathways For Helix Catheter System
BioCardia®, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the outcome of its Pre-Submission Meeting
05-08 20:04
BioCardia and FDA Align on Helix Transendocardial Delivery Catheter Clearance Pathways
BioCardia announced FDA agreement on two pathways for Helix Transendocardial Delivery Catheter marketing clearance, with no concerns raised on safety or performance. FDA preferred simultaneous approval with CardiAMP cell therapy for heart failure. CEO Peter Altman expressed gratitude and aim to pursue both pathways to enhance development and partnerships. Helix enables precise delivery of agents to the heart, while CardiAMP uses bone marrow cells...
05-08 12:00
BioCardia Announces Allowance of Japanese Patent on Proprietary Heart3D™ Fusion Imaging Software for Procedure Planning and Realtime Navigation During CardiAMP Cell Therapy Procedures
BioCardia, a global leader in cellular therapeutics, announces the allowance of a Japanese patent for its Heart3D™ Fusion Imaging software, enhancing treatment planning and navigation for CardiAMP Cell Therapy and Helix™ delivery system. The patent protects technology that combines preoperative 3D images with real-time 2D imaging for improved procedural accuracy. CardiAMP, with FDA Breakthrough designation, uses bone marrow cells to address ische...
04-28 12:00
BioCardia Files Request For FDA Meeting Related To Approval For CardiAMP System For Ischemic Chronic Heart Failure
BioCardia®, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported submission to United States Food and Drug
04-02 22:15
BioCardia Files Request for Meeting With FDA to Discuss Accelerated Approval Pathway for CardiAMP® System in Ischemic Heart Failure
BioCardia, a global leader in cellular therapies, submitted data from its CardiAMP HF clinical study to the FDA and plans to meet with the agency to discuss accelerated approval for the CardiAMP System to treat ischemic chronic heart failure with reduced ejection fraction (HFrEF). The meeting, expected this quarter, will focus on obtaining FDA feedback on the safety, clinical response data, and potential benefits observed in the trial, particular...
04-02 14:11
BioCardia Q4 EPS $(0.06) Beats $(0.17) Estimate
BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.17) by 64.71 percent. This is a 76 percent increase over losses of $(0.25) per share from the same
03-25 04:13
